Research ArticleExperimental Studies
Targeting Ovarian Cancer and Chemoresistance Through Selective Inhibition of Sphingosine Kinase-2 with ABC294640
MARTIN D. WHITE, LUCAS CHAN, JAMES W. ANTOON and BARBARA S. BECKMAN
Anticancer Research September 2013, 33 (9) 3573-3579;
MARTIN D. WHITE
Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA, U.S.A.
LUCAS CHAN
Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA, U.S.A.
JAMES W. ANTOON
Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA, U.S.A.
BARBARA S. BECKMAN
Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA, U.S.A.
In this issue
Anticancer Research
Vol. 33, Issue 9
September 2013
Targeting Ovarian Cancer and Chemoresistance Through Selective Inhibition of Sphingosine Kinase-2 with ABC294640
MARTIN D. WHITE, LUCAS CHAN, JAMES W. ANTOON, BARBARA S. BECKMAN
Anticancer Research Sep 2013, 33 (9) 3573-3579;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Bioactive Sphingolipids as Biomarkers Predictive of Disease Severity and Treatment Response in Cancer: Current Status and Translational Challenges
- The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo
- Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression